The Cost-Effectiveness of Ibrutinib in Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia
trial, oral, once-a-day, first-in-class covalent Bruton’s tyrosine kinase inhibitor ibrutinib was associated with improved Progression-Free Survival (PFS) (Hazard Ratio (HR) 0.106, 95% Confidence Interval ... current…

